| Literature DB >> 22508956 |
Stinne Holm Bergholdt1, Pia Veldt Larsen, Jakob Kragstrup, Jens Søndergaard, Dorte Gilså Hansen.
Abstract
OBJECTIVE: To test the hypothesis that a multimodal intervention giving the general practitioner (GP) an enhanced role in cancer rehabilitation improves patients' health-related quality of life and psychological distress.Entities:
Year: 2012 PMID: 22508956 PMCID: PMC3332246 DOI: 10.1136/bmjopen-2011-000764
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Study flow. GP, general practitioner.
General needs and problems among cancer patients
| Psychological level | Fear of death or recurrence Guilt feelings about being sick Anger at general practitioner or ‘system’ for not having taken action soon enough Troubles adjusting to new self-image Sense of being left in limbo after discharge from the hospital Risk of developing depression Reconsiderations about priorities in life and how one wants to live life with or after a cancer disease Sexual problems |
| Social level | Concerns about the well-being of spouse, children and other relatives Changed body image or sexuality Changed position/status in marriage, in family, at work, etc Concerns about possible infertility caused by treatment Information about patient associations and similar groups for patients and relatives |
| Physical level | Physical capacity according to daily activities, need for special facilities, home care, conversions of the home, etc Need for dietary advice, for example, to prevent undue weight loss Support in order to accept physical changes and late complications like tiredness, amputation, infertility, pain, etc |
| Work-related level | Concerns about losing one's job Concerns about having to give up one's former responsibilities or change field of work due to reduced ability to work Opportunities for financial support during sick-leave, flexible job, etc Support to keep in contact with workplace during sick-leave |
| Financial level | Social rights like mileage allowances, reimbursement of assistive technology, etc Concerns about a decrease in income and consequences hereof in relation to housing, spouse, children, etc Conditions regarding pension or incapacity benefit |
Baseline demographic and medical characteristics for all included patients (n=955)
| Demographic characteristics | Control group (n=469) | Intervention group (n=486) |
| Age, years | ||
| Mean (CI) | 63.6 (62.5 to 64.6) | 63.2 (62.2 to 64.3) |
| Median | 64 | 64 |
| Range | 21–98 | 28–92 |
| Sex | ||
| Male, n (%) | 134 (28.6) | 133 (27.4) |
| Female, n (%) | 335 (71.4) | 353 (72.6) |
| Cancer type | n (%) | n (%) |
| Cancer of breast | 206 (43.9) | 201 (41.4) |
| Cancer of lung | 69 (14.7) | 75 (15.4) |
| Malignant melanoma | 44 (9.4) | 35 (7.2) |
| Cancer of rectum/anus | 33 (7.0) | 45 (9.3) |
| Cancer of colon | 29 (6.2) | 39 (8.0) |
| Cancer of ovaries | 12 (2.6) | 9 (1.9) |
| Cancer of biliary system | 7 (1.5) | 8 (1.6) |
| Cancer of brain | 6 (1.3) | 8 (1.6) |
| Cancer of prostate | 8 (1.7) | 3 (0.6) |
| Cancer of corpus uteri | 6 (1.3) | 5 (1.0) |
| Myelomatosis | 6 (1.3) | 5 (1.0) |
| Lymphoma | 3 (0.6) | 4 (0.8) |
| Unspecified location | 16 (3.4) | 16 (3.3) |
| Other diagnoses | 24 (5.1) | 33 (6.8) |
Health-related quality of life (EORTC QLQ-C30) outcome variables and mean differences at 6 and 4 months (95% CI)
| Outcome variable | 6 months | 14 months | ||||||
| n | Mean (CI) | Mean difference (95% CI) | p Value | n | Mean (CI) | Mean difference (95% CI) | p Value | |
| Global health status/quality of life | ||||||||
| Control group | 297 | 68.0 (65.5 to 70.5) | 246 | 72.8 (70.3 to 75.3) | ||||
| Intervention group | 281 | 69.3 (66.7 to 71.9) | 1.25 (−2.4 to 4.9) | 0.50 | 240 | 72.1 (69.6 to 74.7) | −0.71 (−4.3 to 2.8) | 0.69 |
| Physical functioning | ||||||||
| Control group | 294 | 79.0 (76.4 to 81.5) | 240 | 81.9 (79.3 to 84.5) | ||||
| Intervention group | 280 | 79.7 (77.1 to 82.4) | 0.77 (−2.9 to 4.4) | 0.68 | 234 | 82.0 (79.4 to 84.6) | −0.08 (−3.6 to 3.8) | 0.97 |
| Role functioning | ||||||||
| Control group | 291 | 71.3 (67.7 to 74.9) | 239 | 78.0 (74.4 to 81.7) | ||||
| Intervention group | 277 | 72.5 (68.8 to 76.1) | 1.18 (−3.9 to 6.3) | 0.65 | 235 | 78.8 (75.0 to 82.5) | 0.70 (−4.5 to 5.9) | 0.79 |
| Emotional functioning | ||||||||
| Control group | 293 | 80.5 (78.1 to 83.0) | 240 | 80.7 (77.9 to 83.4) | ||||
| Intervention group | 278 | 81.6 (79.1 to 84.1) | 1.02 (−2.5 to 4.5) | 0.57 | 238 | 80.8 (78.0 to 83.6) | 0.12 (−3.8 to 4.1) | 0.95 |
| Cognitive functioning | ||||||||
| Control group | 290 | 83.0 (80.5 to 85.5) | 245 | 82.6 (79.7 to 85.5) | ||||
| Intervention group | 278 | 83.9 (81.3 to 86.4) | 0.88 (−2.7 to 4.5) | 0.63 | 238 | 85.1 (82.1 to 88.2) | 2.53 (−1.7 to 6.7) | 0.24 |
| Social functioning | ||||||||
| Control group | 295 | 85.7 (83.0 to 88.4) | 242 | 88.2 (85.4 to 91.0) | ||||
| Intervention group | 280 | 86.0 (83.2 to 88.8) | 0.28 (−3.6 to 4.2) | 0.89 | 238 | 87.4 (84.6 to 90.3) | −0.77 (−4.8 to 3.2) | 0.71 |
| Fatigue | ||||||||
| Control group | 292 | 37.4 (34.3 to 40.6) | 244 | 32.1 (28.8 to 35.3) | ||||
| Intervention group | 279 | 34.2 (30.9 to 37.4) | −3.27 (−7.8 to 1.3) | 0.16 | 234 | 32.3 (28.9 to 35.6) | 0.23 (−4.5 to 4.9) | 0.92 |
| Nausea and vomiting | ||||||||
| Control group | 300 | 8.1 (6.1 to 10.0) | 244 | 5.5 (3.9 to 7.2) | ||||
| Intervention group | 284 | 8.0 (6.0 to 10.0) | −0.11 (−2.9 to 2.7) | 0.94 | 236 | 5.6 (3.9 to 7.3) | 0.05 (−2.3 to 2.4) | 0.97 |
| Pain | ||||||||
| Control group | 283 | 23.0 (19.8 to 20.2) | 241 | 21.9 (18.5 to 25.4) | ||||
| Intervention group | 274 | 22.0 (18.8 to 25.3) | −0.95 (−5.5 to 3.6) | 0.68 | 234 | 21.4 (17.8 to 24.9) | −0.56 (−5.5 to 4.4) | 0.83 |
| Dyspnoea | ||||||||
| Control group | 297 | 17.0 (13.9 to 20.2) | 245 | 13.2 (10.0 to 16.5) | ||||
| Intervention group | 286 | 17.9 (14.7 to 21.2) | 0.87 (−3.6 to 5.4) | 0.71 | 233 | 15.4 (11.9 to 18.8) | 2.11 (−2.6 to 6.8) | 0.38 |
| Insomnia | ||||||||
| Control group | 302 | 27.5 (24.0 to 31.0) | 248 | 29.6 (25.6 to 33.6) | ||||
| Intervention group | 285 | 27.3 (23.6 to 30.9) | −0.23 (−5.3 to 4.8) | 0.93 | 240 | 28.5 (24.4 to 32.6) | −1.08 (−6.8 to 4.6) | 0.71 |
| Appetite loss | ||||||||
| Control group | 301 | 14.1 (11.0 to 17.2) | 246 | 9.6 (7.1 to 12.2) | ||||
| Intervention group | 288 | 15.9 (12.7 to 19.0) | 1.79 (−2.7 to 6.2) | 0.43 | 239 | 7.9 (5.4 to 10.5) | −1.67 (−5.3 to 2.0) | 0.37 |
| Constipation | ||||||||
| Control group | 299 | 12.6 (9.7 to 15.5) | 248 | 11.9 (9.0 to 14.91) | ||||
| Intervention group | 284 | 11.3 (8.3 to 14.2) | −1.33 (−5.4 to 2.8) | 0.53 | 236 | 8.9 (5.9 to 11.9) | −3.03 (−5.5 to 2.8) | 0.16 |
| Diarrhoea | ||||||||
| Control group | 299 | 11.3 (8.8 to 13.9) | 250 | 11.4 (8.5 to 14.2) | ||||
| Intervention group | 284 | 11.4 (8.8 to 14.1) | 0.08 (−3.6 to 3.8) | 0.97 | 238 | 10.0 (7.0 to 13.0) | −1.38 (−5.5 to 2.8) | 0.51 |
| Financial difficulties | ||||||||
| Control group | 297 | 7.6 (5.4 to 9.8) | 242 | 6.5 (3.9 to 9.0) | ||||
| Intervention group | 284 | 8.0 (5.7 to 10.2) | 0.34 (−2.8 to 3.5) | 0.83 | 236 | 6.7 (4.1 to 9.4) | 0.27 (−3.4 to 4.0) | 0.89 |
Mean values from 0 to 100. A score of 100 indicates optimal function or maximum symptom intensity (ie, for functional measures, an increase indicates improvement, while for symptoms, an increase indicates worsening).
EORTC QLQ-C30, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30.
Psychological distress (POMS) at 14 months and mean differences between groups (95 CI%)
| Outcome variable | n | Mean range | Mean (95% CI) | Mean difference (95% CI) | p Value |
| Anger/hostility | 0–28 | ||||
| Control group | 223 | 2.03 (1.59 to 2.48) | |||
| Intervention group | 230 | 1.88 (1.43 to 2.33) | −0.15 (−0.79 to 0.48) | 0.64 | |
| Confusion/bewilderment | 0–20 | ||||
| Control group | 229 | 2.45 (2.04 to 2.86) | |||
| Intervention group | 231 | 2.11 (1.69 to 2.53) | −0.34 (−0.92 to 0.25) | 0.26 | |
| Depression/dejection | 0–32 | ||||
| Control group | 223 | 3.85 (3.20 to 4.51) | |||
| Intervention group | 229 | 3.26 (2.61 to 3.92) | −0.59 (−1.52 to 0.34) | 0.21 | |
| Fatigue/inertia | 0–20 | ||||
| Control group | 226 | 4.65 (4.08 to 5.22) | |||
| Intervention group | 234 | 4.14 (3.02 to 4.10) | −0.51 (−1.32 to 0.29) | 0.21 | |
| Tension/anxiety | 0–24 | ||||
| Control group | 226 | 3.82 (3.28 to 4.36) | |||
| Intervention group | 233 | 3.56 (3.02 to 4.10) | −0.26 (−1.02 to 0.50) | 0.50 | |
| Vigour/activity | 0–24 | ||||
| Control group | 218 | 10.28 (9.51 to 11.05) | |||
| Intervention group | 228 | 10.09 (9.31 to 10.86) | −0.20 (−1.29 to 0.89) | 0.72 | |
| Total mood disturbance | 0–124 | ||||
| Control group | 200 | 4.87 (2.29 to 7.45) | |||
| Intervention group | 210 | 4.19 (1.62 to 6.76) | −0.68 (−4.32 to 2.97) | 0.72 |
Mean values of each subscale depends on the number of items related to the individual subscale which varies from 5 to 8, each item ranging from 0 to 4. Total mood disturbance is calculated by summing up the scores on the five negative symptom subscales and subtracting the score on the one positively scored subscale, vigour/activity. A higher score indicates a higher degree of symptoms/feelings within the related subscale.
POMS, Profile of Mood States.